![]() |
![]() |
Legal status
Patent expired
(51) | INT.CL. | A61K 31/7076 | (2006.01) |
A61K 31/397 | (2006.01) | ||
A61P 7/02 | (2006.01) |
(11) | Number of the document | 1237559 |
(13) | Kind of document | T |
(96) | European patent application number | 00982033.3 |
Date of filing the European patent application | 2000-11-29 | |
(97) | Date of publication of the European application | 2002-09-11 |
(45) | Date of publication and mention of the grant of the patent | 2006-07-12 |
(46) | Date of publication of the claims translation | 2006-11-27 |
(86) | Number | PCT/SE2000/002378 |
Date | 2000-11-29 |
(87) | Number | WO 2001/039781 |
Date | 2001-06-07 |
(30) | Number | Date | Country code |
9904377 | 1999-12-01 | SE |
(72) |
DIXON, John, GB
HUMPHRIES, Robert, GB
JARVIS, Gavin, GB
KIRK, Ian, GB
|
(73) |
AstraZeneca AB,
151 85 Södertälje,
SE
|
(74) |
Marius JAKULIS - JASON,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
(54) | Farmaciniai deriniai apimantys P2T receptoriaus antagonistą ir melagatraną |
PHARMACEUTICAL COMBINATIONS COMPRISING A P2T RECEPTOR ANTAGONIST AND MELAGATRAN |
Payment date | Validity (years) | Amount | |
2019-10-31 | 20 | 347.00 EUR |